DDX53 and neoplasm: Figure 3A depicts the aggressive progression of 4T-1 tumors in the inactivated-CMS5-vaccinated cohort. In stark contrast, vaccination with anti-CD25 antibodies and CMS5 cells eradicated 4T-1 tumors (Figure 5B). CT-26 tumors grew swiftly in the inactivated CMS5 vaccine group for the CT-26 challenge investigation, as depicted in Figure 3C. In contrast, the anti-CD25 antibody and inactivated CMS5 vaccination group significantly inhibited CT-26 tumor growth (Figure 5C).